Hypertension in pregnancy is associated with elevated C-reactive protein levels later in life

Journal of Hypertension

Volumn 31, Issue 11, 2013, Pages 2213-2219

  Brown, Catherine M ^a   Turner, Stephen T ^a   Bailey, Kent R ^b   Mosley, Thomas H ^c   Kardia, Sharon L R ^d   Wiste, Heather J ^b   Kullo, Iftikhar J ^b   Garovic, Vesna D ^a  

^a Mayo Clinic College of Medicine   (United States)

^b MAYO CLINIC   (United States)

^c UNIVERSITY OF MISSISSIPPI MEDICAL CENTER   (United States)

^d UNIVERSITY OF MICHIGAN SCHOOL OF PUBLIC HEALTH   (United States)

Author keywords

C reactive protein; cardiovascular disease; hypertension; pregnancy

Indexed keywords

ANTIHYPERTENSIVE AGENT; ANTILIPEMIC AGENT; C REACTIVE PROTEIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR;

ADULT; AGED; ANAMNESIS; ANTIHYPERTENSIVE THERAPY; ARTICLE; BLOOD PRESSURE; BLOOD SAMPLING; BODY MASS; CARDIOVASCULAR DISEASE; CEREBROVASCULAR ACCIDENT; CLINICAL ASSESSMENT; CONTROLLED STUDY; CORONARY ARTERY BYPASS SURGERY; DIABETES MELLITUS; DISEASE ASSOCIATION; DYSLIPIDEMIA; EDUCATIONAL STATUS; FAMILY HISTORY; FEMALE; HORMONE SUBSTITUTION; HUMAN; HYPERTENSION; ISCHEMIC HEART DISEASE; MAJOR CLINICAL STUDY; MATERNAL HYPERTENSION; MULTICENTER STUDY; NULLIPARA; PREECLAMPSIA; PREGNANT WOMAN; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; RACE DIFFERENCE; RISK FACTOR; SMOKING; AGE; BLOOD; CARDIOVASCULAR DISEASES; COMPLICATION; CORONARY ARTERY DISEASE; METABOLISM; MIDDLE AGED; PARITY; PREGNANCY; PREGNANCY COMPLICATION; STATISTICAL MODEL;

ADULT; AGE FACTORS; BLOOD PRESSURE; BODY MASS INDEX; C-REACTIVE PROTEIN; CARDIOVASCULAR DISEASES; CORONARY DISEASE; DIABETES MELLITUS; DYSLIPIDEMIAS; FEMALE; HUMANS; HYPERTENSION; LINEAR MODELS; MIDDLE AGED; PARITY; PREGNANCY; PREGNANCY COMPLICATIONS, CARDIOVASCULAR; RISK FACTORS; STROKE;

EID: 84885640871     PISSN: 02636352     EISSN: 14735598     Source Type: Journal    
DOI: 10.1097/HJH.0b013e3283642f6c     Document Type: Article

References (44)

1. Mosca L, Benjamin EJ, Berra K, Bezanson JL, Dolor RJ, Lloyd-Jones DM, et al. Effectiveness-based guidelines for the prevention of cardiovascular disease in women -2011 update: A guideline from the American Heart Association. Circulation 2011; 123:1243-1262.
2. Roberts JM, Hubel CA. Pregnancy: A screening test for later life cardiovascular disease. Womens Health Issues 2010; 20:304-307.
3. Jonsdottir LS, Arngrimsson R, Geirsson RT, Sigvaldason H, Sigfusson N. Death rates from ischemic heart disease in women with a history of hypertension in pregnancy. Acta Obstet Gynecol Scand 1995; 74:772-776.
4. Smith G, Pell J, Walsh D. Pregnancy complications and maternal risk of ischaemic heart disease: A retrospective cohort study of 129,290 births. Lancet 2001; 357:2002-2006.
5. Wilson BJ, Watson MS, Prescott GJ, Sunderland S, Campbell DM, Hannaford P, et al. Hypertensive diseases of pregnancy and risk of hypertension and stroke in later life: results from cohort study. BMJ 2003; 326:845.
6. Arnadottir GA, Geirsson RT, Arngrimsson R, Jonsdottir LS, Olafsson O. Cardiovascular death in women who had hypertension in pregnancy: A case-control study. BJOG 2005; 112:286-292.
7. Bellamy L, Casas JP, Hingorani AD, Williams DJ. Preeclampsia and risk of cardiovascular disease and cancer in later life: systematic review and meta-analysis. BMJ 2007; 335:974.
8. Garovic VD, Bailey KR, Boerwinkle E, Hunt SC, Weder AB, Curb D, et al. Hypertension in pregnancy as a risk factor for cardiovascular disease later in life. J Hypertens 2010; 28:826-833.
9. Garovic VD, Hayman SR. Hypertension in pregnancy: An emerging risk factor for cardiovascular disease. Nat Clin Pract Nephrol 2007; 3:613-622.
10. Stangl V, Baumann G, Stangl K. Coronary atherogenic risk factors in women. Eur Heart J 2002; 23:1738-1752.
11. Koenig W, Pepys MB. C-reactive protein risk prediction: low specificity, high sensitivity. Ann Intern Med 2002; 136:550-552.
12. Ridker PM, Hennekens CH, Buring JE, Rifai N. C-reactive protein and other markers of inflammation in the prediction of cardiovascular disease in women. N Engl J Med 2000; 342:836-843.
13. Danesh J, Wheeler JG, Hirschfield GM, Eda S, Eiriksdottir G, Rumley A, et al. C-reactive protein and other circulating markers of inflammation in the prediction of coronary heart disease. N Engl J Med 2004; 350:1387-1397.
14. Emerging Risk Factors Collaboration, Kaptoge S, Di Angelantonio E, Pennells L,Wood AM,White IR,Gao P, et al.C-reactiveprotein, fibrinogen, and cardiovascular disease prediction. NEngl J Med 2012; 367:1310-1320.
15. Ridker PM. C-reactive protein and the prediction of cardiovascular events among those at intermediate risk: moving an inflammatory hypothesis toward consensus. J Am Coll Cardiol 2007; 49:2129-2138.
16. ECAT Angina Pectoris Study Group. ECAT Angina Pectoris Study: Baseline associations of haemostatic factors with extent of coronary arteriosclerosis and other coronary risk factors in 3000 patients with angina pectoris undergoing coronary angiography. Eur Heart J 1993; 14:8-17.
17. Kuller LH, Tracy RP, Shaten J, Meilahn EN. Relation of C-reactive protein and coronary heart disease in the MRFIT nested case-control study. Multiple Risk Factor Intervention Trial. Am J Epidemiol 1996; 144:537-547.
18. Ridker PM, Buring JE, Shih J, Matias M, Hennekens CH. Prospective study of C-reactive protein and the risk of future cardiovascular events among apparently healthy women. Circulation 1998; 98:731-733.
19. Tataru MC, Heinrich J, Junker R, Schulte H, von Eckardstein A, Assmann G, et al. C-reactive protein and the severity of atherosclerosis in myocardial infarction patients with stable angina pectoris. Eur Heart J 2000; 21:1000-1008.
20. Ridker PM. Clinical application of C-reactive protein for cardiovascular disease detection and prevention. Circulation 2003; 107:363-369.
21. FBPP Investigators. Multicenter genetic study of hypertension: the Family Blood Pressure Program (FBPP). Hypertension 2002; 39:3-9.
22. Diehl CL, Brost BC, Hogan MC, Elesber AA, Offord KP, Turner ST, et al. Preeclampsia as a risk factor for cardiovascular disease later in life: validation of a preeclampsia questionnaire. Am J Obstet Gynecol 2008; 198:e11-e13.
23. Friedewald WT, Levy RI, Fredrickson DS. Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. Clinical Chem 1972; 18:499-502.
24. Ridker PM, Danielson E, Fonseca FAH, Genest J, Gotto AM, Kastelein JJP, et al. Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein. N Engl J Med 2008; 359:2195-2207.
25. Cushman M, Legault C, Barrett-Connor E, Stefanick ML, Kessler C, Judd HL, et al. Effect of postmenopausal hormones on inflammation-sensitive proteins: the Postmenopausal Estrogen/Progestin Interventions (PEPI) Study. Circulation 1999; 100:717-722.
26. van Baal WM, Kenemans P, van der Mooren MJ, Kessel H, Emeis JJ, Stehouwer CD. Increased C-reactive protein levels during short-term hormone replacement therapy in healthy postmenopausal women. Thromb Haemost 1999; 81:925-928.
27. Kaptoge S, Di Angelantonio E, Lowe G, Pepys MB, Thompson SG, Collins R, et al. C-reactive protein concentration and risk of coronary heart disease, stroke, and mortality: An individual participant metaanalysis. Lancet 2010; 375:132-140.
28. von Versen-Hoeynck FM, Hubel CA, Gallaher MJ, Gammill HS, Powers RW. Plasma levels of inflammatory markers neopterin, sialic acid, and C-reactive protein in pregnancy and preeclampsia. Am J Hypertens 2009; 22:687-692.
29. Qiu C, Luthy DA, Zhang C, Walsh SW, Leisenring WM, Williams MA. A prospective study of maternal serum C-reactive protein concentrations and risk of preeclampsia. Am J Hypertens 2004; 17:154-160.
30. Heart Protection Study Collaborative Group, Emberson J, Bennett D, Link E, Parish S, Danesh J, Armitage J, et al. C-reactive protein concentration and the vascular benefits of statin therapy: An analysis of 20,536 patients in the Heart Protection Study. Lancet 2011; 377:469-476.
31. Sesso HD, Buring JE, Rifai N, Blake GJ, Gaziano JM, Ridker PM. Creactive protein and the risk of developing hypertension. JAMA 2003; 290:2945-2951.
32. Greenland P, Alpert JS, Beller GA, Benjamin EJ, Budoff MJ, Fayad ZA, et al. 2010 ACCF/AHA Guideline for Assessment of Cardiovascular Risk in Asymptomatic Adults: A report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines Developed in Collaboration with the American Society of Echocardiography, American Society of Nuclear Cardiology, Society of Atherosclerosis Imaging and Prevention, Society for Cardiovascular Angiography and Interventions, Society of Cardiovascular Computed Tomography, and Society for Cardiovascular Magnetic Resonance. J Am Coll Cardiol 2010; 56:e50-e103.
33. C Reactive Protein Coronary Heart Disease Genetics Collaboration (CCGC), Wensley F, Gao P, Burgess S, Kaptoge S, Di Angelantonio E, Shah T, et al. Association between C reactive protein and coronary heart disease: mendelian randomisation analysis based on individual participant data. BMJ 2011; 342:d548.
34. Keavney B. C reactive protein and the risk of cardiovascular disease. BMJ 2011; 342:d144.
35. Portelinha A, Cerdeira AS, Belo L, Tejera E, Pinto F, Pinto A, et al. Altered alanine aminotransferase and gamma-glutamyl transpeptidase in women with history of preeclampsia: Association with waist-to-hip ratio and body mass index. Eur J Gastroenterol Hepatol 2009; 21:196-200.
36. Girouard J, Giguere Y, Moutquin JM, Forest JC. Previous hypertensive disease of pregnancy is associated with alterations of markers of insulin resistance. Hypertension 2007; 49:1056-1062.
37. Hubel CA, Powers RW, Snaedal S, Gammill HS, Ness RB, Roberts JM, et al. C-reactive protein is elevated 30 years after eclamptic pregnancy. Hypertension 2008; 51:1499-1505.
38. Ridker PM, Hennekens CH, Rifai N, Buring JE, Manson JE. Hormone replacement therapy and increased plasma concentration of C-reactive protein. Circulation 1999; 100:713-716.
39. Cooper BC, Burger NZ, Toth MJ, Cushman M, Sites CK. Insulin resistance with hormone replacement therapy: Associations with markers of inflammation and adiposity. Am J Obstet Gynecol 2007; 196:123 e1-123 e7.
40. Decensi A, Omodei U, Robertson C, Bonanni B, Guerrieri-Gonzaga A, Ramazzotto F, et al. Effect of transdermal estradiol and oral conjugated estrogen on C-reactive protein in retinoid-placebo trial in healthy women. Circulation 2002; 106:1224-1228.
41. Davison S, Davis SR. New markers for cardiovascular disease risk in women: impact of endogenous estrogen status and exogenous postmenopausal hormone therapy. J Clin Endocrinol Metab 2003; 88:2470-2478.
42. Hemelaar M, van der Mooren MJ, Rad M, Kluft C, Kenemans P. Effects of nonoral postmenopausal hormone therapy on markers of cardiovascular risk: A systematic review. Fertil Steril 2008; 90:642-672.
43. Silvestri A, Gebara O, Vitale C, Wajngarten M, Leonardo F, Ramires JA, et al. Increased levels of C-reactive protein after oral hormone replacement therapy may not be related to an increased inflammatory response. Circulation 2003; 107:3165-3169.
44. Osorio J. Biomarkers: is CRP level useful to guide statin therapy? Lack of evidence from HPS fuels the debate. Nat Rev Cardiol 2011; 8:119.